ImmunoGen watched its shares fall by 50% when partner Roche revealed disappointing results for the pair's targeted cancer drug, casting doubts on the biotech's technology for creating armed antibodies.
Chicago-based private equity group First Analysis expects its $12 million cash infusion into Sonoma Orthopedic Products will be sufficient for the startup to gain FDA clearance for a new ankle implant--as well as to launch it and start to scale up sales.
Roche has been charting promising numbers for its standout breast cancer drugs Kadcyla and Perjeta. But now the next-gen duo has failed to beat Herceptin and chemo in a late-stage study, putting a damper on Roche's plan to expand the market for its new drugs and sending its shares into a downward spiral.
Seattle's Juno Therapeutics managed to top the already superlative expectations for its Wall Street debut, grossing about $264.6 million and pulling off the Nasdaq's biggest 2014 biotech IPO in the waning days of a huge year.
Pet meds developer Aratana Therapeutics has begun a pivotal field study of a new drug to treat postsurgery pain in dogs and reported positive results from another study for a product it hopes to use for the treatment of osteoarthritis in canines.
Yet another big Phase III test of an experimental Alzheimer's drug has flopped. And this time it's Roche's turn to admit defeat.
Thanks to global downsizing, the rapid rise of CROs and mounting pricing pressures, the R&D spends of the world's biggest drug developers remained flat last year, according to a report.
Researchers have found a way to sneak peptides past the immune system by fitting them with cages that cover binding sites on the proteins like a hat. These prevent the binding sites from revealing the peptides' true nature as something from the outside.
After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.
Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.